BiotechTV’s Post

Name: BiotechTV on LinkedIn: 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Checking in with Artiva Biotherapeutics' CEO Fred…
Uploaded: 2024-08-16T00:12:58.950Z
Channel: BiotechTV

BiotechTV

19,477 followers

2mo

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Checking in with Artiva Biotherapeutics' CEO Fred Aslan after the NK cell focused company's $167 million IPO. He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Full video: https://lnkd.in/gFpZ5DNX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

1 Comment

Transcript

Yeah. So we raised $167,000,000. It was an oversubscribed IPO and we did it now first of all to secure the funds that we need in order to run the clinical trials that we're really excited about running, You know, so just kind of fleshing that out a little bit more. We are in a really exciting space, which I'm sure we'll talk about. And we have a number of competitors that are at present public companies and we feel that whenever you are in a very competitive landscape where each company has their own angle and their specific reason. For why their modality could make a difference. If you are not part of the group and also speaking at investor conferences and having analyst coverage and having people follow your company as a private company, it becomes very difficult to be heard given all the noise and appeal. There's really 4 modalities that can credibly go after this notion of a very deep B cell depletion because at the end of the day, we believe that's what drives the mechanism of very deep cell depletion. We know Auto Party can do it right based on the academic data that's out there. And now there's a number of companies. Had been beginning to share data, but another possibility are the aloe carte companies that instead of being autologous they're allergen egg. A third possibility are the allogeneic and NK cell companies as like ourselves. And then the 4th modality are the T cell engagers, which are the monoclonals that are you know by specific they bind to T cells and they bind to the B cells and they try to get rid of them. In our case because we're not genetically engineering our and casel, we rely on a monoclonal such as rituximab. Or obinutuzumab, that monoclonal binds to the target on the B cell and then NK cell. RNK cells do what NK cells do, which is they bind to the FC portion of the monoclonal and then they get activated and they kill the B cell. So we use the monoclonal for targeting and it's rank cell that does the killing. Now there are three specific advantages to not being genetically engineered. The first one is that because we don't introduce any genetic modifications, it makes the manufacturing process a lot simpler and a lot more. Scalable because the genetic engineering introduces variability. There's also a hit in your yield when you're doing genetic engineering. So we don't have to worry about that. The second advantage of not being genetically engineered is you've heard some of the concerns around auto car T potentially leading to secondary malignancies. So any product that is genetically modified has the risk that it could cause secondary malignancies and the FDA is looking at that very closely. The fact that our cells are not genetically modified reduces that risk. And then the third advantage is because we rely on monoclonals for targeting, that means that we could swap out monoclonals. So we could use a CD20 monoclonal to target CD 20 on the B cell or we could use the CD 19 monoclonal or a CD38 monoclonal. So what that does is that gives your one cell therapy an opportunity to target different B cell populations depending on what monoclonal you use. But with the same product, you don't have to engineer a whole new product to go after these other. These cell compartments and right now we're working in combinations with rituximab and obinutuzumab. There are both CD20 monoclonals and our trial and oncology, we utilize rituximab which is a CD20 monoclonal and that's where we saw this deep cell depletion and good efficacy in NHL. So we're starting with those, but we are already taking steps to potentially down the road bring CD 19 or a CD 38 into the clinic in combination with aloe and K.

Lucas Ariel, PhD

2mo

Congrats Fred Aslan for this achievement

To view or add a comment, sign in

More Relevant Posts

Fred Aslan
2mo
Report this post
We covered a lot of important topics in this chat with BiotechTV: ☑️ Why Artiva did an IPO ☑️ How we are thinking about the differentiation of NK cell therapy in autoimmune disease amongst the other modalities: autologous “auto” CAR-T, allogeneic “allo” CAR-T, and other allo NK cell therapies, as well as T cell engagers. ☑️ What do we think success looks like for us over the next year Thanks @BrianOrelli for the first interview since we went public!

BiotechTV

19,477 followers
2mo

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Checking in with Artiva Biotherapeutics' CEO Fred Aslan after the NK cell focused company's $167 million IPO. He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Full video: https://lnkd.in/gFpZ5DNX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

1 Comment
Like Comment
To view or add a comment, sign in
Black Diamond Therapeutics

8,874 followers
7mo Edited
Report this post
Featured in today’s BiotechTV interview with Brad Loncar, our CEO Mark Velleca discussed Black Diamond’s MasterKey approach to precision #oncology with our two clinical-stage programs—BDTX-1535 and BDTX-4933—and the evolving #EGFR mutational landscape. "We realize that there’s upwards of fifty EGFR mutations that can all cause non-small cell lung cancer. This is where MasterKey comes in... nearly all oncogenic mutations of the EGFR cause the receptor to form a conformation that can be uniquely drugged by [BDTX-]1535.” Watch the interview below! #NSCLC

BiotechTV

19,477 followers
7mo Edited

𝐅𝐫𝐨𝐦 𝐁𝐨𝐬𝐭𝐨𝐧: Black Diamond Therapeutics' CEO Mark Velleca on the company's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once. He describes the platform and updates us on Black Diamond's EGFR and BRAF programs. Full video: https://lnkd.in/gE4DUsjh BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
Like Comment
To view or add a comment, sign in
Biotech Hangout

3,908 followers
6mo
Report this post
On today’s #BiotechHangout, Brad Loncar, Daphne Zohar, Luba Greenwood, J.D., and Eric Schmidt discuss inflation effects on biotech stocks, more fallout from the BioSecure Act, #AACR2024, $VRTX acquisition of $ALPN for ~$4.9B in cash, $NVS pays $150M for $ARVN’s prostate cancer therapy, US govt lawsuit against $REGN, LSE challenges w/ companies delisting and leaving @AAMortazavi joins us, some big personnel moves, $XBI and more https://lnkd.in/eVCfC8AV
16 Comments
Like Comment
To view or add a comment, sign in
BioTechniques

3,138 followers
5mo
Report this post
Gain expert insight into the emergence of tumor organoids, tips for best practice when using them and the impact that they are having on the drug development field, in our latest interview with Maryna Panamarova of the Wellcome Sanger Institute Sartorius Read now >>> https://hubs.ly/Q02wPQGn0
Like Comment
To view or add a comment, sign in
Invion Limited

620 followers
5mo
Report this post
Australia's leading independent publication on ASX biotech stocks, Biotech Daily, has featured Invion in its latest article, which was written by acclaimed business journalist and former columnist for The Australian newspaper, tim boreham. Tim delved into the interesting background of Invion and the Photosoft technology ahead of its Phase I/II skin cancer trial. He also looked at the many growth options for Invion and concluded that our clinical-stage company was undervalued. Read this article for free at https://lnkd.in/gWdB3XnE. The article is NOT commissioned by Invion and views expressed in it are that of the author's. #asx #biotech #investing #stockstowatch #cancerresearch #smallcaps
Like Comment
To view or add a comment, sign in
Epicrispr Biotechnologies

3,768 followers
2mo
Report this post
Data we presented this spring at #ASGCT24 showed the promise of our lead candidate, EPI-321, to uniquely address the epigenetic root cause of #FSHD muscular dystrophy. In this interview with CGTLive, our Head of Therapeutics Alexandra Collin de l'Hortet describes the mode of action of EPI-321 and the robust preclinical dataset that supports its potential to have a transformative impact for people with FSHD: https://lnkd.in/e-uufmYv
6 Comments
Like Comment
To view or add a comment, sign in
Wayne Hickok, M.Sc.

Vice President of Sales, North America at Bruker Cellular Analysis
2mo Edited
Report this post
The power and flexibility of #Beacon in 3D animation! Take a journey as if you are a single cell: First discovering an unparalleled breadth of data on your functional abilities, then being recovered alive to either scale up into a breakthrough therapeutic or getting sequenced to connect your genotype to your phenotype! #thepowerofbeacon Bruker Cellular Analysis

Bruker Cellular Analysis

8,019 followers
2mo

Understand the Life of Single-Cells with Bruker Cellular Analysis's Beacon® Platform! Our cutting-edge technology is revolutionizing the way researchers conduct live single-cell multiomics, paving the way for breakthroughs in antibody discovery, cell line development, T cell profiling, and CAR/TCR therapy.

1 Comment
Like Comment
To view or add a comment, sign in
Timothy Kammerer

Customer Engaging, Technical Sales Specialist who bridges the gaps from challenge to solution!!!
2mo
Report this post
Super powerful and completely flexible.

Bruker Cellular Analysis

8,019 followers
2mo

Understand the Life of Single-Cells with Bruker Cellular Analysis's Beacon® Platform! Our cutting-edge technology is revolutionizing the way researchers conduct live single-cell multiomics, paving the way for breakthroughs in antibody discovery, cell line development, T cell profiling, and CAR/TCR therapy.
Like Comment
To view or add a comment, sign in
Syntara

3,200 followers
2w
Report this post
In a recent interview with JustStocks, Syntara's CEO Gary Phillips highlighted the major challenges patients face with current myelofibrosis treatments. Many patients struggle with JAK inhibitors due to side effects, tolerability, and declining blood counts. Our lead asset, SNT-5505, offers a new approach by targeting fibrosis in the bone marrow, aiming to restore healthy blood production. This could not only improve patient quality of life but also create a significant commercial opportunity in a market already exceeding $1 billion USD annually. 📽️ Watch the full interview: https://lnkd.in/gt4b9JrQ #Syntara #SNT #Biotech #myelofibrosis #ClinicalTrials #SNT5505 #BloodCancer #Innovation #PatientCare
Like Comment
To view or add a comment, sign in
Crown Bioscience

33,229 followers
5mo Edited
Report this post
Operate freely with our robust offering of ~500 standard cell lines, licensed, well characterized, and annotated for your screening needs. What sets OmniScreen™ apart? ⬇️ ✅Unmatched Selection: Choose from 30+ cancer indications. ✅Versatile Design: Engage in 3D models, drug combination studies, extended incubation & more. ✅Holistic Solution: From composite biomarker analysis to in vivo follow up with our XenoSelect™ panel. ✅Real-time Insights: Access results promptly with our real-time readouts. Unlock a future where your lead therapeutic agents are the next big breakthrough in preclinical drug development! Register by June 13th ➡️https://hubs.la/Q02yF2fP0 #CancerResearch #CellLines #DrugDevelopment

Unlocking the Potential of Cell Line Screening

crownbio.com
Like Comment
To view or add a comment, sign in

19,477 followers

View Profile Follow

BiotechTV’s Post

Transcript

More Relevant Posts

Explore topics